-Study shows T-cell redirecting therapy can safely be monitored at home, potentially eliminating routine hospitalization after CAR-T and BiTE treatments.

-Outpatient observation cut hospital stays dramatically, with no adverse safety events reported.

-This approach reduces time patients spend away from their families while also freeing up inpatient beds and cutting healthcare costs.

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. 

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orlando, Florida, held Dec. 6 to 9.

Researchers and clinicians from the Icahn School of Medicine at Mount Sinai will present new discoveries in breast cancer biology, treatment, and real-world patient outcomes at the 2025 San Antonio Breast Cancer Symposium (SABCS), Tuesday-Friday, December 9-12, in San Antonio, Texas.  

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity.

A new decision framework developed by MIT researchers shows that, when patients with aggressive T-cell lymphoma relapse within 12 months of initial therapy, their chances for survival decline dramatically. This prognostic marker could help clinicians identify high-risk patients earlier.

New research on public attitudes toward AI indicates that most people are reluctant to let ChatGPT and other AI tools diagnose their health condition, but see promise in technologies that use AI to help diagnose cancer. These and other results of two nationally representative surveys will be presented at the annual meeting of the Society for Risk Analysis Dec. 7-10 in Washington, DC.